title: Orlistat increases serum paraoxonase activity in obese patients.
abstract: OBJECTIVE
  Previous studies have demonstrated that oxidative stress is increased in obese patients. The high-density lipoprotein (HDL) associated human paraoxonase 1 (PON1) can inhibit low-density lipoprotein oxidation and has an antiatherogenic effect. Our objective was to assess the effects of orlistat therapy combined with diet on body mass index (BMI), waist circumference, lipid parameters, blood pressure, serum glucose level and PON1 activity.
  
  
  RESULTS
  A longitudinal, multicenter, randomized study with and without orlistat treatment was performed. One hundred thirty nine otherwise healthy, obese subjects were divided in to two groups: 78 persons received orlistat (120 mg three times a day) combined with diet while 61 persons were kept on diet only. Anthropometrical parameters, serum lipid levels and PON1 activity were measured at baseline and after 6 months of treatment. BMI and waist circumference were reduced more pronouncedly in the orlistat group than in the control group. Patients receiving orlistat also had significantly greater improvements in fasting blood glucose levels and blood pressure. The orlistat-treated group showed a greater reduction in total cholesterol and triglyceride levels. In addition, the serum PON1 activity in these patients was significantly increased compared to the diet-only group.
  
  
  CONCLUSIONS
  The 6-month treatment with orlistat had a beneficial effect on the lipid profile and improved the antioxidant status by increasing serum PON1 activity. However, because of the limited therapeutic effectiveness, obese patients with hypercholesterolemia should receive additional lipid lowering medications.
authors.affiliation: Department of Metabolic Medicine, St. Imre Hospital, Budapest, Hungary.
authors.forename: Mária
authors.initials: M
authors.lastname: Audikovszky
authors.forename: Gyula
authors.initials: G
authors.lastname: Pados
authors.forename: Ildikó
authors.initials: I
authors.lastname: Seres
authors.forename: Mariann
authors.initials: M
authors.lastname: Harangi
authors.forename: Péter
authors.initials: P
authors.lastname: Fülöp
authors.forename: Evelin
authors.initials: E
authors.lastname: Katona
authors.forename: László
authors.initials: L
authors.lastname: Illyés
authors.forename: Gábor
authors.initials: G
authors.lastname: Winkler
authors.forename: Eva M
authors.initials: EM
authors.lastname: Katona
authors.forename: György
authors.initials: G
authors.lastname: Paragh
mesh_terms: D000328:Adult; D000368:Aged; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D043303:Aryldialkylphosphatase / Q000097:blood*; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D007783:Lactones / Q000494:pharmacology / Q000627:therapeutic use*; D015227:Lipid Peroxidation; D008137:Longitudinal Studies; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000188:drug therapy*; D000077403:Orlistat
chemical_list: D019440:Anti-Obesity Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007783:Lactones; D008315:Malondialdehyde; D000077403:Orlistat; D043303:Aryldialkylphosphatase